Patients infected with Mycoplasma genitalium: macrolide resistance and Azithromycin failure


The aim of a study was to determine the efficacy of 1 g Azithromycin ( Zithromax, Zmax ) and alternative antibiotic regimens in a prospective cohort of Mycoplasma genitalium–infected participants, and factors associated with Azithromycin failure.

Consecutive eligible Mycoplasma genitalium–infected men and women attending the Melbourne Sexual Health Centre during the period 2012-2013 were treated with 1 g of Azithromycin and retested by polymerase chain reaction ( PCR ) on days 14 and 28.
Cure was defined as PCR negative on day 28.

Cases failing Azithromycin were treated with Moxifloxacin ( Avelox ), and those failing Moxifloxacin were treated with Pristinamycin.

Pre- and posttreatment samples were assessed for macrolide resistance mutations ( MRMs ) by high-resolution melt analysis.
Mycoplasma genitalium samples from cases failing Moxifloxacin were sequenced for fluoroquinolone resistance mutations.
Multivariable analysis was used to examine associations with Azithromycin failure.

Of 155 participants treated with 1 g Azithromycin, 95 ( 61% ) were cured.

Pretreatment MRM was detected in 56 ( 36% ) participants, and strongly associated with treatment failure ( 87%; adjusted odds ratio, 47.0 ).

All 11 participants who had MRM detected in posttreatment samples failed Azithromycin.

Moxifloxacin was effective in 53 (88% ) of 60 cases failing Azithromycin; all failures had gyrA and parC mutations detected in pretreatment samples.

Six of 7 patients failing Moxifloxacin treatment received Pristinamycin, and all were PCR negative 28 days after Pristinamycin treatment.

In conclusion, researchers have reported a high Azithromycin failure rate ( 39% ) in an Mycoplasma genitalium–infected cohort in association with high levels of pretreatment macrolide resistance.
Moxifloxacin failure occurred in 12% of patients who received Moxifloxacin; all had pretreatment fluoroquinolone mutations detected.
Pristinamycin was highly effective in treating macrolide- and quinolone-resistant strains. ( Xagena )

Bissessor M et al, Clin Infect Dis 2015; 60:1228-1236

XagenaMedicine_2015



Indietro

Altri articoli

Despite limited and conflicting data on the use of Hydroxychloroquine in patients with Covid-19, the FDA ( U.S. Food and...


A potentially life-threatening condition called drug reaction with eosinophilia and systemic symptoms ( DRESS ) has been reported in patients...


Lower respiratory tract infection ( LRTI ) is the third leading cause of death worldwide and the first leading cause...


The current standard of care treatment for Chlamydia sometimes fails to eradicate the disease and the culprit may be in...


Chronic bacterial prostatitis ( CBP ) is frequently diagnosed in men of fertile age, and is characterized by a disabling...


Azithromycin ( Zithromax, Zmax ) use is associated with an increased risk of death from cardiovascular causes among patients at...


The Food and Drug Administration ( FDA ) warned the public that Azithromycin ( Zithromax or Zmax ) can cause...


In a commentary published in the Canadian Medical Association Journal ( CMAJ ), Abby Lippman, an epidemiologist at McGill University...


Oral sex may be a risk factor for nongonococcal urethritis ( NGU ), one of the most common sexually transmitted...